Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026

Novo Nordisk plans to present real-world and clinical data at the EASD conference, including updates on its oral Wegovy pill, cardiometabolic pipeline, and next-generation amylin treatments. The presentations could provide incremental visibility into the company’s obesity and diabetes growth platforms, though the article does not disclose trial results or financial figures.